Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

MLA

Stephanie A. Wankowicz, et al. “Everolimus and Pazopanib (E/P) Benefit Genomically Selected Patients with Metastatic Urothelial Carcinoma.” British Journal of Cancer, vol. 119, Sept. 2018, pp. 707–12. EBSCOhost, https://doi.org/10.1038/s41416-018-0261-0.

APA

Stephanie A. Wankowicz, Eliezer M. Van Allen, Dominick Bossé, Joaquim Bellmunt, Laura Polacek, Nikhil Wagle, Toni K. Choueiri, Sussana Jacobus, Lauren C. Harshman, Irene Moreno, Aly-Khan A. Lalani, Jonathan E. Rosenberg, Kevin Lundgren, & David Y. Takeda. (2018). Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer, 119, 707–712. https://doi.org/10.1038/s41416-018-0261-0

Chicago

Stephanie A. Wankowicz, Eliezer M. Van Allen, Dominick Bossé, Joaquim Bellmunt, Laura Polacek, Nikhil Wagle, Toni K. Choueiri, et al. 2018. “Everolimus and Pazopanib (E/P) Benefit Genomically Selected Patients with Metastatic Urothelial Carcinoma.” British Journal of Cancer 119 (September): 707–12. doi:10.1038/s41416-018-0261-0.